ATXS (Astria Therapeutics) Debt-to-Equity : 0.02 (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics Debt-to-Equity?

Astria Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1.39 Mil. Astria Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $3.67 Mil. Astria Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $289.29 Mil. Astria Therapeutics's debt to equity for the quarter that ended in Mar. 2025 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Astria Therapeutics's Debt-to-Equity or its related term are showing as below:

ATXS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0.02 Max: 0.22
Current: 0.02

During the past 12 years, the highest Debt-to-Equity Ratio of Astria Therapeutics was 0.22. The lowest was -0.01. And the median was 0.02.

ATXS's Debt-to-Equity is ranked better than
88.89% of 1026 companies
in the Biotechnology industry
Industry Median: 0.145 vs ATXS: 0.02

Astria Therapeutics Debt-to-Equity Historical Data

The historical data trend for Astria Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astria Therapeutics Debt-to-Equity Chart

Astria Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

Astria Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Equity	Get a 7-Day Free Trial															-	0.02	0.02	0.02	0.02

Competitive Comparison of Astria Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Astria Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astria Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Astria Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Astria Therapeutics's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Astria Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Astria Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.384	+	3.969)	/	319.263
	=	0.02

Astria Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.392	+	3.671)	/	289.29
	=	0.02

Astria Therapeutics (NAS:ATXS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Astria Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Astria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Boston Wharf Road, 10th Floor, Boston, MA, USA, 02210

Website

https://www.astriatx.com

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Executives

Christopher Morabito	officer: Chief Medical Officer	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews	officer: Chief Business Officer	C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Andrew Komjathy	officer: Chief Commercial Officer	CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols	officer: Chief Scientific Officer	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp	director, 10 percent owner	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck	director	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole	director	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger	officer: Secretary and General Counsel	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142